Oric Pharmaceuticals (ORIC) to Post Earnings on Tuesday

Oric Pharmaceuticals (NASDAQ:ORIC) is expected to announce its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Oric Pharmaceuticals to post earnings of ($0.36) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 3, 2026 at 4:00 PM ET.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02). On average, analysts expect Oric Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oric Pharmaceuticals Price Performance

NASDAQ ORIC traded up $2.41 during trading hours on Tuesday, reaching $13.01. 2,102,163 shares of the company’s stock traded hands, compared to its average volume of 1,788,977. Oric Pharmaceuticals has a 52-week low of $7.23 and a 52-week high of $14.93. The firm has a 50-day simple moving average of $9.77 and a 200 day simple moving average of $10.41. The firm has a market cap of $1.35 billion, a PE ratio of -9.01 and a beta of 1.02.

Analyst Ratings Changes

A number of research analysts recently weighed in on ORIC shares. Citigroup reduced their price objective on Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Benchmark reaffirmed a “buy” rating on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Oric Pharmaceuticals in a research note on Friday, May 22nd. Stifel Nicolaus initiated coverage on shares of Oric Pharmaceuticals in a report on Friday, June 12th. They set a “buy” rating and a $14.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, July 25th. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Oric Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.27.

Hedge Funds Weigh In On Oric Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LLC purchased a new position in shares of Oric Pharmaceuticals during the fourth quarter valued at approximately $102,000. Invesco Ltd. grew its holdings in shares of Oric Pharmaceuticals by 19.8% in the fourth quarter. Invesco Ltd. now owns 109,742 shares of the company’s stock worth $898,000 after acquiring an additional 18,128 shares during the period. XTX Topco Ltd purchased a new stake in Oric Pharmaceuticals during the fourth quarter valued at $904,000. VARCOV Co. bought a new position in Oric Pharmaceuticals in the fourth quarter valued at about $262,000. Finally, Virtus Investment Advisers LLC increased its position in shares of Oric Pharmaceuticals by 141.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 28,361 shares of the company’s stock valued at $232,000 after purchasing an additional 16,594 shares during the last quarter. Institutional investors own 95.05% of the company’s stock.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.